This week in Drug Discovery (20 – 24 October)
News round-up for 20 – 24 October by Bruno Quinney, Content Team at DDW.
This week’s leading story comes from biotech, with Galapagos announcing plans to shelve its cell therapy business and hundreds of employees set to lose theirjobs. Elsewhere, pharma firms are offering discounts to US patients and a new AI model has shed light on how to improve immunotherapy.
The top stories:
Galapagos plans to end cell therapy efforts and close sites
Galapagos has announced its intention to wind down its cell therapy business, following a comprehensive review of strategic alternatives, including a potential divestiture.
Pharma firms offer discounts of up to 85% to US patients
AstraZeneca has become the latest company to lower the cost of medicines for American patients. The company announced an agreement with President Donald Trump’s administration to lower the cost of prescription medicines for American patients “while preserving America’s cutting-edge biopharmaceutical innovation”.
Google AI model reveals new way to improve immunotherapy
A new AI model developed by Google and Yale researchers has revealed a potential novel cancer therapy pathway.
Read more…
Open science collaboration reveals promising new coronavirus antiviral
A promising broad-spectrum coronavirus antiviral pre-clinical candidate, ASAP-0017445, has been discovered.
Neuroscience expert to speak at DDW Symposium
Registration is now open for this free event, which will feature six in-depth presentations from industry experts, a panel discussion examining new processes and technology and an opportunity for networking.
